Matches in SemOpenAlex for { <https://semopenalex.org/work/W2767184039> ?p ?o ?g. }
- W2767184039 endingPage "1924" @default.
- W2767184039 startingPage "1924" @default.
- W2767184039 abstract "<ns4:p>The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal.</ns4:p>" @default.
- W2767184039 created "2017-11-10" @default.
- W2767184039 creator A5013173470 @default.
- W2767184039 creator A5024454882 @default.
- W2767184039 date "2017-10-31" @default.
- W2767184039 modified "2023-09-26" @default.
- W2767184039 title "Recent therapeutic advances in chronic lymphocytic leukemia" @default.
- W2767184039 cites W1016810471 @default.
- W2767184039 cites W1963866495 @default.
- W2767184039 cites W1965159977 @default.
- W2767184039 cites W1966016310 @default.
- W2767184039 cites W1986924929 @default.
- W2767184039 cites W1988795495 @default.
- W2767184039 cites W1999128869 @default.
- W2767184039 cites W2006157886 @default.
- W2767184039 cites W2016042196 @default.
- W2767184039 cites W2017898416 @default.
- W2767184039 cites W2018466312 @default.
- W2767184039 cites W2024216962 @default.
- W2767184039 cites W2025207288 @default.
- W2767184039 cites W2025707347 @default.
- W2767184039 cites W2027345033 @default.
- W2767184039 cites W2030364523 @default.
- W2767184039 cites W2031121711 @default.
- W2767184039 cites W2036379563 @default.
- W2767184039 cites W2039640090 @default.
- W2767184039 cites W2047415399 @default.
- W2767184039 cites W2054220445 @default.
- W2767184039 cites W2055393972 @default.
- W2767184039 cites W2059416155 @default.
- W2767184039 cites W2066331460 @default.
- W2767184039 cites W2066564017 @default.
- W2767184039 cites W2067064694 @default.
- W2767184039 cites W2071549499 @default.
- W2767184039 cites W2076867321 @default.
- W2767184039 cites W2084952484 @default.
- W2767184039 cites W2088580309 @default.
- W2767184039 cites W2089103836 @default.
- W2767184039 cites W2091838381 @default.
- W2767184039 cites W2097290512 @default.
- W2767184039 cites W2103580937 @default.
- W2767184039 cites W2108206643 @default.
- W2767184039 cites W2113278680 @default.
- W2767184039 cites W2115086589 @default.
- W2767184039 cites W2116835043 @default.
- W2767184039 cites W2120319857 @default.
- W2767184039 cites W2125134816 @default.
- W2767184039 cites W2131017274 @default.
- W2767184039 cites W2131823788 @default.
- W2767184039 cites W2134645992 @default.
- W2767184039 cites W2134797116 @default.
- W2767184039 cites W2135216058 @default.
- W2767184039 cites W2135604149 @default.
- W2767184039 cites W2136272158 @default.
- W2767184039 cites W2140052555 @default.
- W2767184039 cites W2140606816 @default.
- W2767184039 cites W2142604595 @default.
- W2767184039 cites W2143766748 @default.
- W2767184039 cites W2145842706 @default.
- W2767184039 cites W2146655236 @default.
- W2767184039 cites W2150487985 @default.
- W2767184039 cites W2153923291 @default.
- W2767184039 cites W2157799317 @default.
- W2767184039 cites W2163690533 @default.
- W2767184039 cites W2171771895 @default.
- W2767184039 cites W2172242534 @default.
- W2767184039 cites W2172718055 @default.
- W2767184039 cites W2191219754 @default.
- W2767184039 cites W2192121806 @default.
- W2767184039 cites W2193225046 @default.
- W2767184039 cites W2221325899 @default.
- W2767184039 cites W2231680293 @default.
- W2767184039 cites W2233614027 @default.
- W2767184039 cites W2295348655 @default.
- W2767184039 cites W2316021978 @default.
- W2767184039 cites W2327057861 @default.
- W2767184039 cites W2341725288 @default.
- W2767184039 cites W2369297677 @default.
- W2767184039 cites W2395887753 @default.
- W2767184039 cites W2408036343 @default.
- W2767184039 cites W2412200636 @default.
- W2767184039 cites W2468773158 @default.
- W2767184039 cites W2469555883 @default.
- W2767184039 cites W2494297194 @default.
- W2767184039 cites W2519500141 @default.
- W2767184039 cites W2527403886 @default.
- W2767184039 cites W2530809101 @default.
- W2767184039 cites W2534349779 @default.
- W2767184039 cites W2546500680 @default.
- W2767184039 cites W2550870820 @default.
- W2767184039 cites W2553911513 @default.
- W2767184039 cites W2557498525 @default.
- W2767184039 cites W2557725070 @default.
- W2767184039 cites W2558511185 @default.
- W2767184039 cites W2561188085 @default.
- W2767184039 cites W2561449166 @default.
- W2767184039 cites W2562706714 @default.
- W2767184039 cites W2563423047 @default.